Literature DB >> 16496289

PTHrP-independent hypercalcemia with increased proinflammatory cytokines and bone resorption in two children with CD19-negative precursor B acute lymphoblastic leukemia.

Hidetaka Niizuma1, Kunihiro Fujii, Atsushi Sato, Ikuma Fujiwara, Junji Takeyama, Masue Imaizumi.   

Abstract

Hypercalcemia in childhood acute lymphoblastic leukemia (ALL) is rare and occasionally associated with parathyroid hormone-related protein (PTHrP). However, the pathogenesis of PTHrP-independent hypercalcemia remains unclear. We report two children with precursor B ALL who had marked hypercalcemia (15.8 and 16.6 mg/dl, respectively) and disseminated osteolysis. Serum tumor necrosis factor-alpha (TNF-alpha) and IL-6 were markedly elevated, whereas 1,25(OH)(2) vitamin D(3), intact PTH and PTHrP were decreased or undetected. Analysis of urinary deoxypyridinoline (DPY) or bone biopsy of the osteolytic lesion showed an increased bone resorption, and administration of bisphosphonate improved the hypercalcemia. Patients had ALL with immunophenotype positive for CD10, CD34, and HLA-DR but negative for CD19 and obtained remission with chemotherapy. These findings suggest that increased osteoclastic bone resorption via stimulation with TNF-alpha and IL-6 may be mechanism causing PTHrP-independent hypercalcemia in some patients with precursor B ALL lacking CD19 expression. 2007 Wiley-Liss, Inc

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16496289     DOI: 10.1002/pbc.20782

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  7 in total

1.  Hypercalcemia and multiple osteolytic lesions in an adult patient with relapsed pre-B acute lymphoblastic leukemia: a case report.

Authors:  G Kaiafa; V Perifanis; N Kakaletsis; K Chalvatzi; A I Hatzitolios
Journal:  Hippokratia       Date:  2015 Jan-Mar       Impact factor: 0.471

2.  Kasabach-Merritt syndrome combined with hypercalcemia: A case report.

Authors:  Runying Zou; Fang Peng; Tian Yu; Saizhen Zeng; Yalan You; Keke Chen; Hui Zou; Xin Tian; Chengguang Zhu; Xiangling He
Journal:  Exp Ther Med       Date:  2017-10-18       Impact factor: 2.447

3.  Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

Authors:  Marco Ruella; David M Barrett; Saad S Kenderian; Olga Shestova; Ted J Hofmann; Jessica Perazzelli; Michael Klichinsky; Vania Aikawa; Farzana Nazimuddin; Miroslaw Kozlowski; John Scholler; Simon F Lacey; Jan J Melenhorst; Jennifer J D Morrissette; David A Christian; Christopher A Hunter; Michael Kalos; David L Porter; Carl H June; Stephan A Grupp; Saar Gill
Journal:  J Clin Invest       Date:  2016-08-29       Impact factor: 14.808

4.  [Acute lymphoblastic leukemia presenting without peripheral blasts but with osteolysis and hypercalcemia in an adolescent. Atypical but not rare].

Authors:  M Karremann; U Schreiner; K-A Büsing; G von Komorowski; M Dürken
Journal:  Orthopade       Date:  2009-08       Impact factor: 1.087

5.  Childhood Sustained Hypercalcemia: A Diagnostic Challenge.

Authors:  Nisa Eda Çullas İlarslan; Zeynep Şıklar; Merih Berberoğlu
Journal:  J Clin Res Pediatr Endocrinol       Date:  2017-04-26

6.  Adult acute precursor B-cell lymphoblastic leukemia presenting as hypercalcemia and osteolytic bone lesions.

Authors:  Nikki Charlotta Paul Granacher; Zwi N Berneman; Wilfried Schroyens; Ann L R Van de Velde; Anke Verlinden; Alain P A Gadisseur
Journal:  Exp Hematol Oncol       Date:  2017-04-11

7.  A successful treatment of hypercalcemia with zoledronic acid in a 15-year-old boy with acute lymphoblastic leukemia.

Authors:  Hye-Jin Park; Eun-Jin Choi; Jin-Kyung Kim
Journal:  Ann Pediatr Endocrinol Metab       Date:  2016-06-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.